Vertex Pharmaceuticals (NASDAQ: VRTX) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...

The Department of Health and Human Services says Vertex is 'grasping at straws' in a lawsuit challenging the agency’s ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

The Dutch fashion retailer’s Omoda Stylist platform leverages Google Cloud’s Vertex AI platform and Gemini models for a tailored shopping experience.

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

Study explains long-standing question of why Huntington’s disease symptoms typically do not appear until midlife even though patients are born with the mutation. Analyses reveal that the repeated DNA ...

Hitachi Vantara, the data storage, infrastructure, and hybrid cloud management subsidiary of Hitachi, Ltd. (TSE: 6501), today announced that Malayala Manorama, India's second-largest newspaper by ...